BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...million in its series C in 2017. Patel was CMO at Lyell Immunopharma Inc.Proteomic platform company Nautilus...
...Jian Kang as VP of IP. BC Staff Merck KGaA Johnson & Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus...
BioCentury | May 22, 2020
Finance

Nautilus raises $76M series B to deliver next-generation proteomics to the lab

...Looking to elevate the proteome to the same level as the genome for biotech R&D, Nautilus...
...existing investors AME Cloud Ventures, Andreessen Horowitz, Bolt and Madrona Venture Group. The round brings Nautilus...
...of existing technologies, which the company said are slow, expensive and often provide incomplete data, Nautilus...
BioCentury | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

...its founding in 2015. Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus...
BioCentury | Feb 17, 2014
Analyst Picks & Changes

Analyst picks & changes

...in 2014 and $37M in 2015. Last December, Depomed gained U.S. rights to Cambia from Nautilus...
BioCentury | Dec 23, 2013
Company News

Depomed, Nautilus Neurosciences sales and marketing update

...Depomed gained U.S. rights to Cambia diclofenac oral solution for migraines from Nautilus. Nautilus will receive...
...will be responsible for third-party royalties and up to $10 million in third-party sales milestones. Nautilus...
...to Treximet, a combination of sumatriptan and naproxen sodium. Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Nautilus...
BioCentury | Dec 19, 2013
Company News

Depomed jumps on U.S. acquisition of migraine drug

...U.S. rights to migraine drug Cambia diclofenac oral solution from Nautilus Neurosciences Inc. (Bedminster, N.J.). Nautilus...
...versus other acute migraine products." The company expects the move to increase annual sales of Nautilus...
...responsible for third party royalties and up to $10 million in third party sales milestones. Nautilus...
BioCentury | Dec 24, 2012
Company News

CytoDyn management update

...Fla. Business: Infectious Hired: Michael Mulholland as treasurer, corporate secretary and CFO, formerly CFO of Nautilus...
BioCentury | Oct 15, 2012
Company News

Stellar Pharmaceuticals sales and marketing update

...2010, Tribute received an exclusive license to develop and commercialize the product in Canada from Nautilus...
BioCentury | Apr 2, 2012
Clinical News

Cambia diclofenac regulatory update

...2010, Tribute received an exclusive license to develop and commercialize the product in Canada from Nautilus...
...Co. Ltd. (Nagoya, Japan) in 2009 (see BioCentury, June 29, 2009 & Nov. 22, 2010). Nautilus...
BioCentury | Nov 14, 2011
Company News

Nautilus Neurosciences board of directors update

Nautilus Neurosciences Inc. , Bedminster, N.J. Business: Neurology Appointed: Peter Lankau as executive chairman, formerly CEO of Logical Therapeutics Inc. WIR Staff...
Items per page:
1 - 10 of 46
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...million in its series C in 2017. Patel was CMO at Lyell Immunopharma Inc.Proteomic platform company Nautilus...
...Jian Kang as VP of IP. BC Staff Merck KGaA Johnson & Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. eFFECTOR Therapeutics Inc. Nautilus...
BioCentury | May 22, 2020
Finance

Nautilus raises $76M series B to deliver next-generation proteomics to the lab

...Looking to elevate the proteome to the same level as the genome for biotech R&D, Nautilus...
...existing investors AME Cloud Ventures, Andreessen Horowitz, Bolt and Madrona Venture Group. The round brings Nautilus...
...of existing technologies, which the company said are slow, expensive and often provide incomplete data, Nautilus...
BioCentury | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

...its founding in 2015. Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus...
BioCentury | Feb 17, 2014
Analyst Picks & Changes

Analyst picks & changes

...in 2014 and $37M in 2015. Last December, Depomed gained U.S. rights to Cambia from Nautilus...
BioCentury | Dec 23, 2013
Company News

Depomed, Nautilus Neurosciences sales and marketing update

...Depomed gained U.S. rights to Cambia diclofenac oral solution for migraines from Nautilus. Nautilus will receive...
...will be responsible for third-party royalties and up to $10 million in third-party sales milestones. Nautilus...
...to Treximet, a combination of sumatriptan and naproxen sodium. Depomed Inc. (NASDAQ:DEPO), Menlo Park, Calif. Nautilus...
BioCentury | Dec 19, 2013
Company News

Depomed jumps on U.S. acquisition of migraine drug

...U.S. rights to migraine drug Cambia diclofenac oral solution from Nautilus Neurosciences Inc. (Bedminster, N.J.). Nautilus...
...versus other acute migraine products." The company expects the move to increase annual sales of Nautilus...
...responsible for third party royalties and up to $10 million in third party sales milestones. Nautilus...
BioCentury | Dec 24, 2012
Company News

CytoDyn management update

...Fla. Business: Infectious Hired: Michael Mulholland as treasurer, corporate secretary and CFO, formerly CFO of Nautilus...
BioCentury | Oct 15, 2012
Company News

Stellar Pharmaceuticals sales and marketing update

...2010, Tribute received an exclusive license to develop and commercialize the product in Canada from Nautilus...
BioCentury | Apr 2, 2012
Clinical News

Cambia diclofenac regulatory update

...2010, Tribute received an exclusive license to develop and commercialize the product in Canada from Nautilus...
...Co. Ltd. (Nagoya, Japan) in 2009 (see BioCentury, June 29, 2009 & Nov. 22, 2010). Nautilus...
BioCentury | Nov 14, 2011
Company News

Nautilus Neurosciences board of directors update

Nautilus Neurosciences Inc. , Bedminster, N.J. Business: Neurology Appointed: Peter Lankau as executive chairman, formerly CEO of Logical Therapeutics Inc. WIR Staff...
Items per page:
1 - 10 of 46